Kyle Mullen

Kyle Mullen

Auto-generated profile, based on publicly available information

Kyle Mullen

American Academy of Orthopaedic Surgeons, Rosemont, IL, USA

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 February 2022 in Journal of the American Academy of Orthopaedic Surgeons
Verified
Journal Article
Closed access
ASAhmed Siddiqi
Ahmed Siddiqi
VAVignesh K. Alamanda
Vignesh K. Alamanda
JBJohn W. Barrington
John W. Barrington
ACAntonia F. Chen
Antonia F. Chen
ADAyushmita De
Ayushmita De
BSBryan D. Springer
Bryan D. Springer
Background: The purpose of this study was to evaluate outcomes and complications because it relates to surgeon and hospital volume for patients undergoing primary total hip arthroplasty (THA) and total knee arthroplasty (TKA) using the American Joint Replacement Registry from 2012 to 2017. Methods: A retrospective study was conducted on Medicare-eligible cases of primary elective THAs and TKAs reported to the American Joint Replacement Registry database and was linked with the available Centers of Medicaid and Medicare Services claims and the National Death Index data from 2012 to 2017. Surgeon and hospital volume were defined separately based on the median annual number of anatomic-specific total arthroplasty procedures performed on patients of any age per surgeon and per hospital. Values were aggregated into separate surgeon and hospital volume tertile groupings and combined to create pairwise comparison surgeon/hospital volume groupings for hip and knee. Results: Adjusted multivariable logistic regression analysis found low surgeon/low hospital volume to have the greatest association with all-cause revisions after THA (odds ratio [OR], 1.63, 95% confidence interval [CI], 1.41-1.89, P < 0.0001) and TKA (OR, 1.72, 95% CI, 1.44-2.06, P < 0.0001), early revisions because of periprosthetic joint infection after THA (OR, 2.50, 95% CI, 1.53-3.15, P < 0.0001) and TKA (OR, 2.18, 95% CI, 1.64-2.89, P < 0.0001), risk of early THA instability and dislocation (OR, 2.47, 95% CI, 1.77-3.46, P < 0.0001), and 90-day mortality after THA (OR, 1.72, 95% CI, 1.27-2.35, P = 0.0005) and TKA (OR, 1.47, 95% CI, 1.15-1.86, P = 0.002). Conclusion: Our findings demonstrate considerably greater THA and TKA complications when performed at low-volume hospitals by low-volume surgeons. Given the data from previous literature including this study, a continued push through healthcare policies and healthcare systems is warranted to direct THA and TKA procedures to high-volume centers by high-volume surgeons because of the evident decrease in complications and considerable costs associated with all-cause revisions, periprosthetic joint infection, instability, and 90-day mortality. Level of Evidence: III

1 May 2021 in Journal of the American Academy of Orthopaedic Surgeons
Verified
Journal Article
Closed access
ACAntonia F. Chen
Antonia F. Chen
KMKyle Mullen
Kyle Mullen
FCFrancisco Casambre
Francisco Casambre
VVVidya Visvabharathy
Vidya Visvabharathy
GBGregory A. Brown
Gregory A. Brown
Background: There are roughly 14 million adults in the United States presenting with symptomatic osteoarthritis (OA) of the knee. Nerve radiofrequency ablation (RFA) is a nonsurgical procedure for the management of knee OA symptoms, and no previous systematic review has been performed comparing geniculate nerve RFA to other nonsurgical treatments. Questions/Purposes: (1) How does geniculate nerve RFA compare with other nonsurgical modalities for patients with knee OA about pain, function, quality of life, and composite scores? and (2) How does geniculate nerve RFA compare with other nonsurgical modalities for patients with knee OA about adverse events (AEs)? Methods: A systematic literature review was conducted within PubMed, EMBASE, and Cochrane Central Register of Controlled Trials to identify all studies from 1966 to 2019 evaluating the relative effectiveness of geniculate nerve thermal (heated or cooled) RFA compared with other nonsurgical treatments for knee OA. Two independent abstractors reviewed and analyzed the literature including comparators such as intra-articular (IA) corticosteroids, IA hyaluronic acid, NSAIDs, acetaminophen (paracetamol), and control/sham procedures. Inclusion was based on the following criteria: English language, human subjects, symptomatic knee OA, and patient-reported outcomes. Results: Five high-quality and two moderate-quality randomized controlled trials (RCTs) met the inclusion criteria for this review. The results showed consistent agreement across all RCTs in favor of geniculate nerve thermal RFA use for nonsurgical treatment of knee OA. One high-quality RCT and one moderate-quality RCT found geniculate nerve RFA to provide statistically significant outcome improvement compared with control or sham procedures regarding pain, function, quality of life, and composite scores. When compared with IA corticosteroids and hyaluronic acid, geniculate nerve RFA also provided notable improvement in pain, function, and composite scores (visual analog scale, Western Ontario, and McMaster Universities Arthritis Index, and Oxford Knee Score). RFA was markedly favored for all pain and composite outcomes (Western Ontario and McMaster Universities Arthritis Index and visual analog scale). The included RCTs did not report any serious AEs related to geniculate nerve RFA. Discussion: These results demonstrate geniculate nerve thermal RFA to be a superior nonsurgical treatment of knee OA compared with NSAIDs and IA corticosteroid injections. None of the RCTs reported any serious AEs with geniculate nerve thermal RFA, as opposed to known cardiovascular, gastrointestinal, and renal AEs for NSAIDs and accelerated cartilage loss and periprosthetic infection risk for IA corticosteroid injections. Level of Evidence: Level I

21 November 2024 in Clinical Orthopaedics and Related Research
Verified
Journal Article
Closed access
GKGregory J. Kirchner
Gregory J. Kirchner
JSJeffrey B. Stambough
Jeffrey B. Stambough
EJEmily Jimenez
Emily Jimenez
KMKyle Mullen
Kyle Mullen
LNLucas E. Nikkel
Lucas E. Nikkel
Background: Previously, we conducted a retrospective study of American Joint Replacement Registry (AJRR) data that examined the 2-year odds of revision between robotic-assisted and nonrobotic-assisted TKA, and we found no benefit to robotic assistance. However, proponents of robotic assistance have suggested that robot platforms confer more accurate bone cuts and precise implant sizing that might promote osteointegration of cementless implants by limiting micromotion at the bone-implant interface that could lead to aseptic loosening. Therefore, it seems important specifically to evaluate the odds of revision among patients with cementless implants only within our previous study population. Questions/purposes: (1) After controlling for potentially confounding variables, such as surgeon, institution, and patient comorbidity profile, was robotic assistance associated with a decreased odds of 2-year revision of cementless TKA for any reason compared with cementless TKAs performed without robotic assistance? (2) After again controlling for potentially confounding variables, was robotic assistance associated with a decreased odds of 2-year revision of cementless TKA for particular revision indications (such as aseptic loosening, infection, instability, or pain) compared with the cementless TKAs performed without robotic assistance? Methods: Using the AJRR, a retrospective cohort of patients ≥ 65 years of age with osteoarthritis who underwent primary TKA with cementless femur and tibial components from January 2017 through March 2020 was identified. Procedures performed with hybrid fixation (cement only on the tibia but not on the femur, or vice versa) were excluded. The AJRR was selected because it is the largest arthroplasty registry in the world by annual procedure volume, and it contains a data linkage with inpatient and outpatient Medicare claims data to ensure near-complete 2-year follow-up. A total of 9220 patients were identified, and robotic assistance was used in 45% (4130) of procedures. Patient age did not differ between groups (72 ± 5 years versus 72 ± 5 years; p = 0.29). However, the robotic-assisted cohort had a slightly higher proportion of female patients (56% [2332 of 4130] versus 53% [2693 of 5090]; p = 0.002) and higher Charlson comorbidity index (CCI) (2.9 ± 0.9 versus 2.8 ± 0.9; p = 0.003). Therefore, a mixed-effects model was used to analyze the ORs for all-cause linked revision with robotic assistance and was adjusted for age, gender, CCI, surgeon, and institution. Subanalyses were performed on indications for revision. A power analysis demonstrated the ability to measure a difference as small as one-half SD between risk of revision within each cohort (specifically, moderate effect sizes based on Cohen d). Results: After controlling for potentially confounding variables, such as surgeon, location of surgery, and patient comorbidity profile, we found no difference regarding odds of all-cause revision between robotic-assisted and nonrobotic-assisted cementless TKA (OR of robotic-assisted versus nonrobotic-assisted cementless TKA 0.8 [95% CI 0.5 to 1.3]; p = 0.41). There were no differences in reasons for revision between robotic-assisted and nonrobotic-assisted cementless TKA, such as mechanical loosening (OR 3.2 [95% CI 0.8 to 12]; p = 0.09) and infection (OR 1.5 [95% CI 0.8 to 2.6]; p = 0.19). Conclusion: We found no evidence that robotic assistance improves the odds of cementless implant survival free from revision at 2 years. Importantly, the differences in odds of revision beyond 2 years as a function of robotic assistance in cementless TKA remains unknown and warrants further population-level investigation, but until or unless robotic assistance proves its value in well-designed studies in terms of endpoints that patients can perceive (such as pain, function, or survivorship), we recommend against widespread adoption until further evidence becomes available. Additionally, we encourage surgeons and healthcare facilities using robotic assistance in cementless TKAs to study its impact on patient outcomes, if any. Level of Evidence: Level III, therapeutic study.

28 February 2024 in The Journal of Arthroplasty
Verified
Journal Article
Closed access
DMDavid P. Martin
David P. Martin
DRDavid M. Rossi
David M. Rossi
BBBrett R. Bukowski
Brett R. Bukowski
OSOlivia N. Sterling
Olivia N. Sterling
KMKyle J. Mullen
Kyle J. Mullen
RIRichard L. Illgen
Richard L. Illgen